艾昆纬 IQV 深 沪
交易中 03-25 11:45:35 美东时间
165.29
-0.800
-0.48%
华盛通- 最 高171.07
- 今 开169.11
- 成交量 26.23万股
- 最 低 163.25
- 昨 收 166.09
- 总市值 277.69亿
- 52周最高 247.045
- 市盈率 静 21.09
- 换手率 0.16%
- 52周最低 134.645
- 委 比 71.43%
- 总股本 1.68亿
- 历史最高 285.61
- 量 比 0.47
- 振 幅 4.71%
- 历史最低 81.79
- 每 手 1
- 风险率 30.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
Aquestive Therapeutics appoints Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, succeeding Lori J. Braender, who will continue as Corporate Secretary. Zalewski, with extensive experience in life sciences law, will support the company's mission to advance Anaphylm, the first oral epinephrine rescue medication. Braender, after nearly eight years in her roles, will focus on corporate governance. The c...
03-20 11:00
EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market
Scienture signs agreements expanding Rezenopy naloxone for opioid overdose access to 5,000 US institutions and first responders.
03-11 19:46
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
SCIENTURE HOLDINGS, INC. announced the formalization of multiple commercial Group Purchasing Organization (GPO) agreements for REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, enabling access to over 5,000 healthcare institutions, representing potential penetration into approximately 60% of the U.S. institutional market. The agreements expand reach across EMS providers and rehabilitation centers, enhancing market access for this high-dose naloxone nas...
03-11 12:05
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
Medpace, IQVIA upgraded at Barclays; says AI concerns are overdone
As part of a broader review of life science and diagnostic tools stocks, Barclays upgraded contract research organizations IQVIA Holdings (IQV) and Medpace Holdings (MEDP) on Friday, noting that conce...
03-07 02:44
Wiley Q3 FY2026 operating income rises 21% to USD 63 million
Wiley Q3 FY2026 operating income rises 21% to USD 63 million Wiley reported third-quarter fiscal 2026 results for the period ended January 31, 2026, with revenue of USD 410 million (+1.0%), operating income of USD 63 million (+21.0%), net income of USD 30 million, and diluted EPS of USD 0.56. Adjust
03-05 20:31
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
RBC Capital Initiates Coverage On IQVIA Holdings with Outperform Rating, Announces Price Target of $221
RBC Capital analyst Ryan Halsted initiates coverage on IQVIA Holdings (NYSE:IQV) with a Outperform rating and announces Price Target of $221.
03-03 23:22
BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes opened higher on Wednesday after volatile sessions ear
02-25 22:39
